• • Combination therapy (amlodipine 5 mg + perindopril 4 mg) achieved a mean SBP reduction of 23.5 mmHg (from 158.2±12.3 to 134.7±8.9 mmHg) over 24 weeks, significantly greater than monotherapy's 18.2 mmHg (p<0.01), indicating enhanced efficacy for high-risk CHD patients.
• • Target BP (<140/90 mmHg) was attained in 82.5% of patients on combination therapy versus 65.0% on monotherapy (p<0.01), a clinically meaningful improvement that could reduce cardiovascular events.
• • Adverse event rates were similar (12.5% vs 10.8%, p>0.05), with no serious adverse events, demonstrating that the combination is well-tolerated and safe for long-term use.
• • No significant changes in renal function, electrolytes, or liver enzymes were observed, confirming the metabolic neutrality of the regimen, which is crucial for patients with comorbid conditions.